JP Morgan Chase
MBRX icon

JP Morgan Chase’s Moleculin Biotech MBRX Stock Holding History

JP Morgan Chase’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Hold
0
– -$3 – 7598
2024
Q3 		– Hold
0
– – – 7344
2024
Q2 		– Hold
0
– – – 7160
2024
Q1 		– Hold
0
– – – 7073
2023
Q4 		– Hold
0
– – – 7220
2023
Q3 		– Hold
0
– – – 7231
2022
Q2 		– Sell
-2
Closed -$1K – 6708
2022
Q1 		$1K Buy
+2
New +$1.15K ﹤0.01% 6485

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AWM
Atticus Wealth Management Palm Beach Gardens, Florida $420M AUM 23.31% 1-Year Est. Return

JP Morgan Chase's MBRX Position: Q4 2024 in Review

JP Morgan Chase held its Moleculin Biotech (MBRX) position steady in Q4 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7598.

JP Morgan Chase first reported a position in MBRX in Q1 2022 and has held it in 1 quarter since. The position peaked at $1K in Q1 2022. 20 funds tracked by Wall St. Rank hold MBRX as of Q4 2024.

  • JP Morgan Chase held 0 shares of Moleculin Biotech worth $0 as of Q4 2024.
  • JP Morgan Chase left its Moleculin Biotech share count unchanged in Q4 2024.
  • Moleculin Biotech made up ﹤0.01% of JP Morgan Chase's portfolio in Q4 2024, its #7598 holding.
  • JP Morgan Chase first reported a position in Moleculin Biotech in Q1 2022 and has held it in 1 quarter since.
  • JP Morgan Chase's Moleculin Biotech position peaked at $1K in Q1 2022.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.